Get started

Financials · ACRS

Aclaris Therapeutics Inc. (ACRS) financials

For the twelve months ended Sep 30, 2026, Aclaris Therapeutics Inc. reported $6.40M of revenue and -$79.63M of net income.

Revenue, TTM
$6.40M
Revenue growth, YoY
-59.3%
Net income, TTM
-$79.63M
Net margin
-1244.1%
Free cash flow, TTM
-$75.31M
EPS, diluted, TTM
-$0.58
Cash
$20.39M
P/S
105.06
Market cap
$672.5M
Annual revenue$7.83M
FY2017FY2025
Annual net income-$64.92M
FY2016FY2025
Annual free cash flow-$47.22M
FY2016FY2025

ACRS revenue and earnings growth

ACRS revenueQ3 2026$1.48M

Quarter YoY
-55.1%
QoQ
-9.1%
FY YoY
-58.2%
5Y CAGR
+3.8%

ACRS revenue was $1.48M in fiscal Q3 2026 (ended Sep 30, 2026), down 55.1% from a year earlier and down 9.1% from the prior quarter. For the full fiscal 2025 it was $7.83M, down 58.2% from fiscal 2024. Compound annual growth was +3.8% over 5 years. It rose in 5 of the last 8 fiscal years.

ACRS net incomeQ3 2026-$18.51M

ACRS net income was -$18.51M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.61M a year earlier. For the full fiscal 2025 it was -$64.92M, compared with -$132.06M in fiscal 2024.

ACRS EPSQ3 2026-$0.12

ACRS diluted EPS was -$0.12 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.12 a year earlier. For the full fiscal 2025 it was -$0.53.

ACRS free cash flowQ3 2026-$24.09M

ACRS free cash flow was -$24.09M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$10.96M a year earlier. For the full fiscal 2025 it was -$47.22M, compared with -$20.20M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$7.83M$18.72M$31.25M$29.75M$6.76M$6.48M$4.23M$6.15M$1.68M-
Cost of revenue$2.09M$2.79M$3.42M$4.02M$4.71M$5.13M$4.05M$4.33M$1.21M-
Gross profit$5.74M$15.93M$27.83M$25.73M$2.05M$1.35M$172.0K$3.24M$476.0K-
Research and development$52.65M$33.59M$98.38M$77.81M$43.81M$29.34M$64.17M$60.84M$35.80M$33.48M
Selling, general and admin$21.97M$22.20M$32.41M$25.13M$23.62M$20.53M$27.83M$25.76M$18.95M$11.80M
Operating income-$76.38M-$141.93M-$97.36M-$89.85M-$89.72M-$50.91M-$111.06M-$84.78M-$54.36M-$48.57M
Pre-tax income-$64.92M-$132.06M-$88.85M-$86.91M-$90.86M-$51.34M-$113.54M-$82.10M-$70.35M-$48.08M
Income tax---$367.0K---$182.0K---$1.83M-
Net income-$64.92M-$132.06M-$88.48M-$86.91M-$90.86M-$51.02M-$161.35M-$132.74M-$68.52M-$48.08M
EPS, basic-$0.53-$1.71-$1.27-$1.33-$1.60-$1.20-$3.90-$4.03-$2.44-$2.25
EPS, diluted-$0.53-$1.71-$1.27-$1.33-$1.60-$1.20-$3.90-$4.03-$2.44-$2.25
Diluted shares122.6M77.3M69.8M65.2M56.7M42.5M41.3M32.9M28.1M21.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$19.96M$24.57M$39.88M$45.28M$27.35M$22.06M$35.94M$57.02M$20.20M$30.17M
Receivables-$318.0K$298.0K$484.0K$623.0K$772.0K$704.0K$563.0K$481.0K-
Inventory------$0$791.0K--
Current assets$96.32M$125.95M$128.86M$231.55M$205.03M$57.49M$83.80M$179.50M$200.22M$138.56M
Goodwill-------$18.50M$18.50M-
Total assets$160.46M$220.33M$197.41M$254.60M$251.21M$70.78M$98.30M$275.57M$243.51M$176.09M
Current liabilities$28.64M$31.60M$30.95M$21.94M$22.93M$14.87M$22.43M$27.34M$12.76M$6.22M
Total debt-----$10.65M-$29.91M--
Total liabilities$57.38M$64.77M$40.23M$56.98M$53.87M$33.13M$28.39M$60.44M$18.25M$6.59M
Shareholders' equity$103.08M$155.55M$157.18M$197.62M$197.34M$37.65M$69.91M$215.12M$225.26M$169.49M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$47.11M-$20.07M-$78.33M-$67.57M-$52.13M-$38.63M-$96.44M-$100.81M-$54.66M-$34.60M
Capital expenditures$111.0K$121.0K$1.31M$605.0K$308.0K$453.0K$1.61M$1.36M$1.24M$232.0K
Free cash flow-$47.22M-$20.20M-$79.63M-$68.17M-$52.44M-$39.09M-$98.06M-$102.17M-$55.90M-$34.84M
Investing cash flow$48.37M-$69.77M$46.22M$12.63M-$167.63M$6.39M$105.68M$9.37M-$55.69M-$61.90M
Financing cash flow-$5.86M$74.54M$26.71M$72.87M$225.05M$18.37M-$30.32M$128.26M$100.39M$116.83M
Stock-based compensation$12.38M$10.86M$20.54M$15.04M$14.06M$11.21M$16.18M$20.05M$14.43M$6.10M
Depreciation and amortization$454.0K$807.0K$863.0K$797.0K$923.0K$1.32M$6.41M$1.88M$402.0K$120.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-58.2%-40.1%5.0%340.1%4.3%53.3%-31.3%265.5%--
Gross margin73.3%85.1%89.0%86.5%30.3%20.8%4.1%52.7%28.3%-
Operating margin-975.9%-758.2%-311.6%-302.0%-1327.1%-785.4%-2627.3%-1378.3%-3230.0%-
Net margin-829.6%-705.5%-283.1%-292.1%-1344.0%-787.0%-3817.2%-2158.0%-4071.5%-
Free cash flow margin-603.4%-107.9%-254.8%-229.1%-775.7%-603.0%-2319.8%-1661.0%-3321.3%-
Return on equity-63.0%-84.9%-56.3%-44.0%-46.0%-135.5%-230.8%-61.7%-30.4%-28.4%
Return on assets-40.5%-59.9%-44.8%-34.1%-36.2%-72.1%-164.1%-48.2%-28.1%-27.3%
Current ratio3.363.994.1610.558.943.873.746.5615.6922.27
Debt to equity-----0.28-0.14--

Source: XBRL data Aclaris Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ACRS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ACRS$6.40M-59.3%-$79.63M-1244.1%$672.5M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

ACRS FAQ

9 questions
  • What is ACRS revenue?
    Aclaris Therapeutics Inc. (ACRS) reported $6.40M of revenue for the twelve months ended Sep 30, 2026. That is down 59.3% from the year before. Revenue for fiscal 2025 was $7.83M.
  • Is ACRS profitable?
    No. Aclaris Therapeutics Inc. reported a net loss of $79.63M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ACRS have?
    Aclaris Therapeutics Inc. reported $20.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ACRS revenue growing?
    Aclaris Therapeutics Inc.'s revenue changed -58.2% in fiscal 2025, to $7.83M. Its compound annual growth rate was +3.8% over 5 years.
  • What is ACRS gross margin?
    Aclaris Therapeutics Inc.'s gross profit was $5.07M on $6.40M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 79.2%.
  • What is ACRS free cash flow?
    Aclaris Therapeutics Inc. generated -$75.31M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$75.21M less capital expenditures.
  • What is ACRS earnings per share?
    Diluted earnings per share were -$0.58 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ACRS last report financial results?
    The latest statements here come from Aclaris Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this ACRS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Aclaris Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.